Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited Fundamental Analysis
Clinuvel Pharmaceuticals Limited (CLVLF) shows moderate financial fundamentals with a PE ratio of 16.42, profit margin of 38.07%, and ROE of 15.79%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 7.76%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 69.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CLVLF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentCLVLF demonstrates superior asset utilization.
Valuation Score
ExcellentCLVLF trades at attractive valuation levels.
Growth Score
ModerateCLVLF shows steady but slowing expansion.
Financial Health Score
ExcellentCLVLF maintains a strong and stable balance sheet.
Profitability Score
ExcellentCLVLF achieves industry-leading margins.
Key Financial Metrics
Is CLVLF Expensive or Cheap?
P/E Ratio
CLVLF trades at 16.42 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, CLVLF's PEG of -1.80 indicates potential undervaluation.
Price to Book
The market values Clinuvel Pharmaceuticals Limited at 2.47 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 17.39 times EBITDA. This signals the market has high growth expectations.
How Well Does CLVLF Make Money?
Net Profit Margin
For every $100 in sales, Clinuvel Pharmaceuticals Limited keeps $38.07 as profit after all expenses.
Operating Margin
Core operations generate 46.16 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.79 in profit for every $100 of shareholder equity.
ROA
Clinuvel Pharmaceuticals Limited generates $13.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Clinuvel Pharmaceuticals Limited generates strong operating cash flow of $41.18M, reflecting robust business health.
Free Cash Flow
Clinuvel Pharmaceuticals Limited generates strong free cash flow of $40.88M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.81 in free cash annually.
FCF Yield
CLVLF converts 6.85% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.42
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.80
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.47
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.26
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.002
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.66
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How CLVLF Stacks Against Its Sector Peers
| Metric | CLVLF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.42 | 29.45 | Better (Cheaper) |
| ROE | 15.79% | 779.00% | Weak |
| Net Margin | 38.07% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 9.66 | 4.65 | Strong Liquidity |
| ROA | 13.31% | -19344.00% (disorted) | Strong |
CLVLF outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Clinuvel Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
187.02%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
113.75%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
184.92%
Industry Style: Defensive, Growth, Innovation
High Growth